Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2027

Conditions

NF2 Deficiency

Interventions

GENETIC

ST002

Single multi-point intra-tumoral injection of ST002, a lentiviral vector designed to drive expression of the NF2 protein product, Merlin.

Trial Locations (1)

Shuhang Wang, Beijing

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06834438 - Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002 | Biotech Hunter | Biotech Hunter